Business ❯ Biotechnology

Pharmaceuticals

Drug Development Vaccine Development Acquisitions Clinical Trials Cancer Treatment Oncology Gene Therapy Biosimilars Regulatory Affairs Research and Development

ImmunityBio Faces Investor Lawsuits After FDA Rebukes Anktiva Marketing

The filings show how an FDA advertising rebuke can quickly spill into shareholder lawsuits.

Stories older than 24h

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

PTAB Reaffirms Broad Institute’s Priority for CRISPR-Cas9 in Eukaryotic Cells

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

Codexis Posts Q4 Beat on Merck Deal, Sets 2026 Outlook

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Fujifilm Opens £400m Billingham Expansion, Creating the UK’s Largest Single‑Use Biologics CDMO

CSL Profit Slides on Plasma Weakness as Buyback Hits $750 Million, Interim CEO Appointed

Vertex Heads Into Feb. 12 Earnings With Cautious Market After Mixed Year

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

CEPI Taps Samsung Biologics to Pre-Position Rapid Vaccine Manufacturing for Future Outbreaks

Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion